Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
Top Cited Papers
- 1 January 2020
- journal article
- research article
- Published by Elsevier in The Lancet Oncology
- Vol. 21 (1) , 44-59
Abstract
No abstract availableKeywords
Funding Information
- F. Hoffmann-La Roche
This publication has 21 references indexed in Scilit:
- What are the treatment patterns and overall survival (OS) in patients with metastatic triple-negative breast cancer (mTNBC) in US clinical practice?Annals of Oncology, 2017
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trialThe Lancet, 2017
- Survival with metastatic breast cancer based on initial presentation, de novo versus relapsedBreast Cancer Research and Treatment, 2016
- PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomasHuman Pathology, 2016
- Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2015
- Prognostic and predictive value of PDL1 expression in breast cancerOncotarget, 2014
- Measures of Outcome in Metastatic Breast Cancer: Insights From a Real-World ScenarioThe Oncologist, 2014
- PD-L1 Expression in Triple-Negative Breast CancerCancer Immunology Research, 2014
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast CancerJournal of Clinical Oncology, 2010
- The B7-H1 (PD-L1) T Lymphocyte-Inhibitory Molecule Is Expressed in Breast Cancer Patients with Infiltrating Ductal Carcinoma: Correlation with Important High-Risk Prognostic FactorsNeoplasia, 2006